

**MTCL2 is a new Golgi-resident microtubule-regulating protein,
essential for organizing asymmetric microtubule network**

Risa Matsuoka[†], Masateru Miki[†], Sonoko Mizuno, Yurina Ito, Atsushi Suzuki*

Molecular Cellular Biology Laboratory, Yokohama City University Graduate School of
Medical Life Science, 1-7-29 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan

[†] These authors contributed this work equally.

* Corresponding author: Atsushi Suzuki

1-7-29, Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan

TEL: 045-508-7238; E-mail: abell@tsurumi.yokohama-cu.ac.jp

Running title: MTCL2 is a novel microtubule-regulating protein

Keywords: MTCL1, SOGA, Golgi ribbon, microtubule, polarity

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Abstract

The Golgi apparatus plays important roles in organizing the asymmetric microtubule network essential for polarized vesicle transport. The Golgi-associated coiled-coil protein MTCL1 is crucially involved in Golgi functioning by interconnecting and stabilizing microtubules on the Golgi membrane through its N- and C-terminal microtubule-binding domains. Here, we report the presence of a mammalian paralog of MTCL1, named MTCL2, lacking the N-terminal microtubule-binding domain. MTCL2 localizes to the Golgi membrane through the N-terminal region and directly binds microtubules through the conserved C-terminal domain without promoting microtubule stabilization. Knockdown experiments demonstrated essential roles of MTCL2 in accumulating MTs around the Golgi and regulating the Golgi ribbon structure. *In vitro* wound healing assays further suggested a possible intriguing activity of MTCL2 in integrating the centrosomal and Golgi-associated microtubules around the Golgi ribbon, thus supporting directional migration. Altogether, the present results demonstrate that cells utilize two members of the MTCL protein family to differentially regulate the Golgi-associated microtubules for controlling cell polarity.

19

Introduction

20

21 The microtubule (MT) cytoskeleton plays essential roles in organizing intracellular
22 structures by mediating the transport and positioning of organelles. Generally, in animal
23 cells MTs radiate from the centrosome, where MT nucleation and attachment of MT
24 minus ends occur predominantly (Conduit et al., 2015; Vorobjev and Nadezhdina, 1987).
25 However, the presence of other subsets of MTs that lack centrosome anchoring (non-
26 centrosomal MTs) has been documented over the last decade and their physiological
27 significance has received considerable attention from cell biologists (Akhmanova and
28 Hoogenraad, 2015; Bartolini and Gundersen, 2006; Nishita et al., 2017). In particular,
29 non-centrosomal MTs appear in differentiated cells, such as epithelial, neuronal, or
30 skeletal muscle cells, where the centrosome loses its MT nucleation activity (Muroyama
31 and Lechler, 2017). Contrasting to centrosomal MTs, which exhibit dynamic instability
32 at their plus ends and radiate rather symmetrically, non-centrosomal MTs are stabilized
33 by mechanisms that are not completely clarified (Baas et al., 2016; Pepperkok et al., 1990),
34 and are frequently bundled and organized into cell-type specific arrays that support cell
35 polarization (Bacallao et al., 1989; Hahn et al., 2019; Mogensen et al., 1989; Oddoux et
36 al., 2013). Recent studies have revealed that less differentiated cultured cells containing
37 centrosomal MTs can also develop non-centrosomal MTs (Meiring et al., 2020). The most
38 intensely studied non-centrosomal MTs of this kind are the Golgi-associated MTs, which
39 nucleate from or attach their minus ends to the Golgi membrane (Efimov et al., 2007;
40 Rivero et al., 2009; Wu et al., 2016). These MTs are stabilized and asymmetrically
41 accumulated around the Golgi as dense networks (Chabin-Brion et al., 2001), and connect
42 the individual Golgi stacks laterally (Miller et al., 2009). As a result, these Golgi-

43 associated MTs facilitate the formation of vertebrae-specific, crescent-like assembly of
44 Golgi stacks, called the Golgi ribbon, which is required for the polarization of vesicle
45 transport and thus directional migration (Wei and Seemann, 2010; Yadav et al., 2009).

46 The molecular mechanisms by which Golgi-associated MTs nucleate from or attach
47 their minus ends to the Golgi membrane have been intensely studied (Wu and Akhmanova,
48 2017; Wu et al., 2016; Yang et al., 2017). However, how these MTs are specifically
49 stabilized and accumulated remained unclear until recently, when we identified a novel
50 MT-regulating protein named MTCL1 (microtubule crosslinking factor 1) (Sato et al.,
51 2013; Sato et al., 2014). MTCL1 is an MT lattice-binding protein that specifically
52 condenses to the Golgi membrane and plays essential roles in the cross-linkage and
53 stabilization of Golgi-associated microtubules. MTCL1 is a long coiled-coil protein with
54 two MT-binding domains (MTBDs) at the N- and C-terminal regions. The C-terminal
55 MTBD (C-MTBD) has the ability to stabilize the polymerization state of MTs, and was
56 shown to be essential for specific stabilization of Golgi-associated MTs (Abdul Kader et
57 al., 2017; Sato et al., 2014). In contrast, the N-terminal MTBD (N-MTBD) of MTCL1,
58 binds MTs without affecting their stability and induces MT bundling only when it
59 dimerizes through the downstream coiled-coil rich region (Abdul Kader et al., 2017).

60 Invertebrate genomes do not encode homologous proteins of MTCL1, suggesting
61 that the MT-regulating activities of MTCL1 are specifically utilized in vertebrates. In
62 addition, vertebrate genomes encode a single paralog of MTCL1, which we named
63 MTCL2 (GenBank accession number: NM_001164663). The deduced amino acid
64 sequence showed significant homology with MTCL1 in the central coiled-coil region and
65 the C-MTBD, but not in the N-MTBD (Fig. 1A-C). This suggests that vertebrates exploit
66 another MT-regulating protein with similar but not identical activity to that of MTCL1.

67 In this study, we aimed to examine whether MTCL2 functions as a homolog of MTCL1,
68 and if so, to dig into the similarities and differences between these MTCLs. The first
69 question is particularly important considering that a mouse MTCL2 isoform lacking the
70 203 N-terminal amino acids has already been reported as SOGA (suppressor of glucose
71 from autophagy) with completely different functions than those of MTCL1 (Fig. 1A)
72 (Combs and Marliss, 2014; Cowherd et al., 2010). According to the previous paper,
73 SOGA is translated as a membrane-spanning protein and cleaved into two halves in the
74 ER of hepatocytes (Cowherd et al., 2010). The resultant N-terminal fragment is released
75 into the cytoplasm to suppress autophagy by interacting with the Atg12/Atg5 complex,
76 whereas the C-terminal fragment is secreted after further cleavage (see Fig. 1A, boxed
77 illustration). In this context, we first analyzed the expression, subcellular localization, and
78 functions of MTCL2, and concluded that uncleaved MTCL2 works as a novel MT-
79 regulating protein in the cytosol, at least in several cell lines. Our results indicated that
80 MTCL2 associates with the Golgi membrane, where it crosslinks but does not stabilize
81 MTs through the conserved C-MTBD. Knockdown experiments demonstrated that these
82 activities of MTCL2 are required for the accumulation of MTs around the Golgi and the
83 clustering of Golgi stacks into a compact Golgi ribbon. *In vitro* wound healing assays
84 further suggested a possible intriguing activity of MTCL2 in integrating the centrosomal
85 and Golgi-associated MTs around the Golgi ribbon, thus being essential for directional
86 migration. Since MTCL1 and 2 localize on microtubules in a mutually exclusive manner,
87 the present results demonstrate that cells utilize two members of the MTCL protein family
88 to differentially regulate the Golgi-associated MTs for controlling cell polarity.

89

90

Results

91

92 **MTCL2 is expressed predominantly as an 180kDa full-length protein without**
93 **cleavage**

94

95 SOGA, a mouse MTCL2 isoform lacking the 203 N-terminal amino acids, is cleaved
96 into several fragments in hepatocytes (see boxed illustration in Fig. 1A) (Cowherd et al.,
97 2010). To examine whether MTCL2 functions as an MTCL1 paralog, we first analyzed
98 the molecular mass of MTCL2 in several cell lines including a human liver cancer cell
99 line, HepG2. Based on epitope position, the commercially available anti-SOGA antibody
100 was predicted to detect an 80kDa N-terminal fragment if MTCL2 was subjected to
101 cleavage as reported previously (Fig. 1A) (Cowherd et al., 2010). As shown in Fig. 1D,
102 V5-tagged mouse MTCL2 exogenously expressed in HEK293T cells was detected as a
103 single major band with a molecular mass of around 180kDa, consistent with the nominal
104 molecular weight of 185,656 predicted from the cDNA sequence of mouse MTCL2
105 (GenBank accession number: NM_001164663), although very weak signals were
106 observed just below the major band. Anti-V5 antibody also revealed the same staining
107 pattern (data not shown). When the antibody was examined for extracts of HeLa-K,
108 HepG2, and RPE1 cells, bands with a similar molecular mass to V5-mMTCL2 were
109 mainly detected, and they disappeared in cells subjected to MTCL2 knockdown (Fig. 1D).
110 As several minor bands were also absent in knockdown cells, they may represent isoforms
111 or cleaved products of MTCL2, particularly in RPE1 cells. However, most of their
112 molecular masses are larger than 135kDa. Therefore, these data indicate that endogenous
113 MTCL2 in these cells is not subjected to the cleavage previously reported for SOGA.

114 Western blotting analysis of various mouse tissue extracts also revealed a similar 180kDa
115 band as a major band in the lung, testis, ovary, cerebrum, and cerebellum (Fig.1 E). These
116 results suggest that MTCL2 is expressed as a full-length protein rather ubiquitously. The
117 tissue distribution pattern of MTCL2 is similar to that of MTCL1 (Satake et al., 2017),
118 indicating the possibility that these two MTCL family members work simultaneously.

119

120 **MTCL2 colocalizes with the perinuclear microtubules and Golgi membrane**

121

122 Next, we examined the subcellular localization of MTCL2 in HeLa-K cells. The anti-
123 SOGA antibody revealed granular signals accumulating near the perinuclear region (Fig.
124 2A), which disappeared in MTCL2 knockdown cells (see Fig. 5 and 6). In the perinuclear
125 region, these granular signals were frequently arranged in linear order along MTs (Fig.
126 2A, enlarged view). Consistently, MTCL2 showed strong colocalization with stabilized
127 perinuclear MTs stained with anti-acetylated tubulin antibody (Fig. 2B, C). However,
128 MTCL2 signal was not significantly observed around dynamic MTs invading the
129 peripheral region (Figs.2A and 3). These results suggest that MTCL2 preferentially
130 associates with Golgi-associated MTs, similar to MTCL1(Sato et al., 2014). In fact,
131 MTCL2 signals partially overlapped with those of the cis-Golgi marker proteins GM130
132 (Fig. 2C) and GS28 (Fig. 3). Close inspection using super-resolution microscopy further
133 revealed the possibility that MTCL2 mediates the association of the Golgi membrane with
134 stabilized MTs (Fig. 2D, arrows).

135 To further support the above results, we next examined the subcellular localization
136 of exogenously expressed MTCL2 (Supplementary Fig.1). When highly expressed in
137 HeLa-K cells, exogenous MTCL2 induced thick MT bundles and disrupted the normal

138 Golgi ribbon structure (Supplementary Fig. 1A, B, arrows). However, when the
139 expression was suppressed to endogenous levels, exogenous MTCL2 mimicked the
140 subcellular localization of endogenous MTCL2, by showing accumulation to one side of
141 the perinuclear region and colocalization with Golgi-associated MTs.

142 In Fig. 3, we compared the subcellular localization of MTCL2 with MTCL1 and
143 another MT lattice-binding protein MAP4, a classical MAP expressed in HeLa-K cells
144 (Chapin and Bulinski, 1991). MAP4 exhibits a rather continuous distribution on MTs
145 without strong preference for Golgi-associated MTs. In contrast, both MTCL1 and 2
146 intermittently localize on MTs and are specifically condensed on Golgi-associated MTs.
147 These results indicate that the localization pattern of MTCL2 is indeed a characteristic
148 feature of MTCL protein family members.

149

150 **MTCL2 associates with MTs and the Golgi membrane independently through the**
151 **C-terminal and N-terminal regions, respectively**

152

153 To determine which regions are responsible for the subcellular localizations of
154 MTCL2, we subdivided the molecule into three fragments, N, M, and C, and expressed
155 them as V5-tagged forms to examine their localization in HeLa-K cells (Fig. 4A, B). As
156 expected, the C-terminal fragment of MTCL2 (C), which contained the region
157 corresponding to MTCL1 C-MTBD, colocalized with MTs (Fig. 4B, top panels). Direct
158 binding with MTs was further confirmed using a shorter fragment of MTCL2 (CT1), still
159 containing the putative C-MTBD (Fig 4A and C). CT1 fused with MBP (maltose-binding
160 protein), but not MBP alone, was co-sedimented with MTs *in vitro* when purified from *E.*
161 *coli* and mixed with taxol-stabilized MTs (Fig. 4C). A smaller C-terminal fragment, which

162 completely corresponded to the C-MTBD of MTCL1, colocalized with MTs, although it
163 tended to accumulate in the nucleus (Fig.8D). Taken together, these results indicate that
164 MTCL2 directly interacts with MTs through the conserved C-terminal region
165 corresponding to the C-MTBD of MTCL1.

166 Fig. 4B also indicates that, contrasting to MTCL1 (Fig. 4B, bottom panels), the N-
167 terminal fragment of MTCL2 (N) did not colocalize with MTs when expressed in HeLa-
168 K cells. Instead, this fragment clearly colocalized with the Golgi membrane stained with
169 anti-GM130 antibody. Together with the results that the middle fragment, M, distributed
170 diffusely without showing any discrete localizations (Fig. 4B), these results indicate that
171 MTCL2 associates with MTs and the Golgi membrane independently through the C-
172 terminal and N-terminal regions, respectively. Since the C-terminal fragment did not
173 show preferential binding to the perinuclear MTs (Fig. 4B), these results suggest that
174 preferential association of MTCL2 with the perinuclear, Golgi-associated MTs is the
175 consequence of the dual binding activity of MTCL2 with MTs and the Golgi membrane.

176

177 **MTCL2 depletion reduced the accumulation of perinuclear MTs and induced lateral** 178 **expansion of the Golgi ribbon structures**

179

180 To explore the physiological function of MTCL2, we next analyzed the effects of
181 MTCL2 knockdown in HeLa-K cells. For this purpose, we first established heterogeneous
182 stable cells expressing mouse MTCL2 in a doxycycline-dependent manner (see Materials
183 and Methods). When cells were transfected with control siRNA in the absence of
184 doxycycline (without exogenous MTCL2 expression), many cells showed strong
185 accumulation of MTs around the perinuclear region at which endogenous MTCL2 is

186 concentrated (Fig. 5A). In contrast, cells subjected to MTCL2 knockdown in the absence
187 of doxycycline exhibited complete loss of MTCL2 signal and severely reduced
188 accumulation of MTs around the perinuclear region (Fig. 5A). The specificity of these
189 knockdown effects was confirmed by a rescue experiment in which doxycycline was
190 added to induce expression of RNAi-resistant MTCL2 (mouse MTCL2) at endogenous
191 levels. Under these conditions, many cells restored MT accumulation in the perinuclear
192 region, where the exogenous MTCL2 is concentrated. Fig. 5B shows the quantitatively
193 analyzed data of these experiments. Here, we estimated the asymmetric distribution of
194 MTs by calculating the skewness of the intensity distribution for tubulin signals within
195 each cell (Fig. 5B, top panel). In control cells, the pixel intensity of tubulin signals was
196 distributed with skewness ~ 0.8 (median), whereas in MTCL2 knockdown cells this value
197 decreased to ~ 0.5 , indicating a more symmetric distribution of MTs. Expression of RNAi-
198 resistant mouse MTCL2 restored the value to ~ 0.65 , statistically supporting its rescue
199 activity. We further confirmed that expression of an MTCL2 mutant lacking C-MTBD
200 (mMTCL2 Δ C-MTBD) could not restore the perinuclear accumulation of MTs in MTCL2
201 knockdown cells (Fig. 5C, D). These results suggest that MTCL2 promotes the
202 accumulation of MT through MT binding via C-MTBD.

203 Interestingly, MTCL2 knockdown also affected the morphology of Golgi ribbons (Fig.
204 6). Contrasting to control cells, which showed a compact crescent-like morphology of the
205 Golgi ribbon at one side of the nucleus, MTCL2 knockdown cells exhibited abnormally
206 expanded Golgi ribbons along the nucleus (Fig. 6A). The median expansion angle (θ) of
207 the Golgi apparatus (see top panel of Fig. 6B) was 84.3° for control cells, whereas it
208 significantly increased to 106.3° in MTCL2 knockdown cells (Fig. 6B). Again, expression
209 of RNAi-resistant MTCL2 reduced the angle with a median value of 76.6° , indicating that

210 MTCL2 is essential for compact accumulation of the Golgi ribbon. The MTCL2 Δ C-
211 MTBD mutant failed to rescue this phenotype (Fig. 6C and D). Similar effects of MTCL2
212 knockdown were observed in RPE1 cells (Supplementary Fig. 3). Altogether, these results
213 demonstrate that MTCL2 plays important roles in the perinuclear accumulation of MTs
214 and the morphology of Golgi ribbons.

215

216 **MTCL2 depletion resulted in defects in cell migration**

217

218 Previous studies have demonstrated that the Golgi ribbon structure and its associated
219 MTs are essential for maintaining directed cell migration due to its essential roles in the
220 polarized transport of vesicles (Bergmann et al., 1983; Miller et al., 2009; Rivero et al.,
221 2009; Sato et al., 2014; Yadav et al., 2009). Therefore, we next examined whether MTCL2
222 depletion affected directed cell migration during *in vitro* wound healing process.

223 First, HeLa-K cells transfected with control or MTCL2 siRNA were grown to a
224 confluent monolayer and scratched with a micropipette tip to initiate directional migration
225 into the wound. In control cells at the wound edge, reorientation of the Golgi and
226 elongation of a densely aligned MT toward the wound were clearly observed (Fig. 7A).
227 In MTCL2 knockdown cells, reorientation of the Golgi was reduced but not severely
228 affected. Nevertheless, cells lacking MTCL2 exhibited randomly oriented MTs and failed
229 to align them toward the wound (Fig. 7A).

230 Despite the significant difference in MT organization in cells at the wound edge, we
231 could not estimate the effects of MTCL2 knockdown on directional migration because
232 HeLa-K cells migrated very slowly. Thus, we used RPE1 cells to estimate wound healing
233 velocity, and found that cells lacking MTCL2 migrated significantly slower than control

234 cells (Fig. 7B, Supplementary Movies 1 and 2). By comparing the normalized areas newly
235 covered by migrated cells, the directed migration velocity of MTCL2 knockdown cells
236 was estimated to be ~50% of that of control cells (Fig. 7B). Time-lapse analysis of
237 differential interference contrast (DIC) images indicated that cells lacking MTCL2
238 exhibited abnormally elongated shapes and showed less efficiency in extending
239 lamellipodia (Supplementary Movie 2). Reorientation of the Golgi position toward the
240 wound was observed in MTCL2 knockdown cells to a similar extent as control cells (Fig.
241 7C, D). In addition, in contrast to HeLa-K cells, polarized elongation of MTs toward the
242 wound was also observed, even in MTCL2 knockdown cells (Fig. 7C). However, the
243 proximal ends of these MTs looked rather unfocused. Close inspection demonstrated that
244 in MTCL2 knockdown cells at the wound edge the Golgi ribbon was frequently separated
245 from the centrosome and sometimes detached from the nucleus (Fig. 7 C and E). As a
246 result, the centrosomal MTs and Golgi-associated MTs elongated from different positions
247 towards the wound, and could be clearly discerned in many MTCL2 knockdown cells.
248 This was in sharp contrast to control cells, in which the centrosome and Golgi-ribbon
249 were tightly linked near the nucleus and the proximal part of the centrosomal and Golgi-
250 associated MTs were focused together indistinguishably. These results suggest an
251 intriguing possibility that MTCL2 plays an essential role in integrating the centrosomal
252 and Golgi-associated MTs by crosslinking them on the Golgi membrane.

253

254 **Relationship between MTCL2 and MTCL1**

255

256 Finally, we examined the relationship between MTCL1 and MTCL2 with respect to
257 their localization and function. To compare their localization, we analyzed HeLa-K cells

258 stably expressing V5-tagged MTCL2 at a level comparable to that of the endogenous one
259 (Fig. 8A). Triple staining of the cells with anti-V5, anti-MTCL1, anti- α -tubulin
260 antibodies revealed that granular signals of MTCL1 and 2 hardly overlapped even when
261 both of them were on MTs. These results indicate that MTCL1 and 2 interact with MTs
262 in a mutually exclusive manner. Next, we examined the interaction between endogenous
263 MTCL1 and 2 in HeLa-K cells, since these coiled-coil proteins were shown to form a
264 heterogeneous complex when simultaneously overexpressed in HEK293T cells (data not
265 shown). In Fig. 8B, we immunoprecipitated endogenous MTCL1 from HeLa-K cells and
266 examined the presence of MTCL2 in the immunocomplex. Although the experiment was
267 performed to precipitate whole MTCL1 in the input (data not shown), less than 10% of
268 MTCL2 in the input was condensed in the immunocomplex. This indicates that a
269 substantial fraction of MTCL2 exists without forming a heterooligomer with MTCL1.
270 These results are consistent with the immunostaining results in Fig. 8A, and indicate that
271 MTCL1 and 2 exist independently in the same cells. We also confirmed that MTCL2
272 knockdown did not affect the perinuclear localization of MTCL1, supporting that both
273 proteins localize independently on Golgi-associated MTs.

274 In a previous study, we demonstrated that MTCL1 knockdown does not affect MT
275 organization significantly, but specifically reduces anti-acetylated tubulin signal on the
276 perinuclear MTs (Sato et al., 2014). This is in sharp contrast to the present results that
277 MTCL2 knockdown markedly affected MT organization (Fig. 5A), but did not
278 significantly reduce tubulin acetylation signals (Fig. 8C). These results suggest the
279 possibility that the C-MTBD of MTCL2 lacks MT stabilization activity due to the
280 sequence diversity of MTCL1 CMTB (red line in Fig. 1C). To examine this possibility,
281 we expressed GFP-CMTB of MTCL1 and 2 in HeLa-K cells, and analyzed their effects

282 on tubulin acetylation, as a marker of MT stabilization (Fig. 8D). As previously
283 demonstrated, GFP-MTCL1 C-MTBD strongly induced tubulin acetylation in the MTs to
284 which it associated even at low concentration (Abdul Kader et al., 2017). However, the
285 association of GFP-MTCL2 C-MTBD with MTs did not induce tubulin acetylation even
286 at higher concentrations. Noteworthy, the CMTB of MTCL1, but not MTCL2 caused MT
287 bundling, which is considered a secondary effect of MT stabilization (also see Fig. 4B).
288 We confirmed these results quantitatively by western blotting analysis of HEK293T cell
289 extracts expressing each CMTB construct (Fig. 8E) (Sato et al., 2014). The results clearly
290 indicate that expression of MTCL1 C-MTBD but not MTCL2 C-MTBD dramatically
291 increased tubulin acetylation. Taken together, these results demonstrate that MTCL1 and
292 2 independently localized to the Golgi-associated MTs and exert distinct MT-regulating
293 functions to differentially contribute to the development of cell polarity.
294

295

Discussion

296

297 In the present study, we demonstrate that MTCL2, the mammalian MTCL1 paralog, is a
298 novel MT-regulating protein that preferentially localizes to the Golgi membrane and plays
299 essential roles in perinuclear MT accumulation and Golgi ribbon morphology.

300 A shorter variant of MTCL2 was reported in 2010 and named SOGA (Cowherd et al.,
301 2010), the putative internal signal sequence of which was hypothesized to direct its
302 translation and cleavage in ER. The present data indicate that, albeit containing whole
303 SOGA sequences, MTCL2 is mainly expressed in a full-length form without cleavage and
304 functions in the cytosol as an MT-regulating protein. We cannot completely exclude the
305 possibility that a minor fraction of MTCL2 is processed in cultured cells as previously
306 predicted. Alternatively, this process could occur predominantly in the liver to function
307 as a suppressor of glucose by autophagy (SOGA). However, the results presented here
308 are highly consistent with the notion that this gene product dominantly functions as an
309 MT-regulating protein, but not as a SOGA. Based on these results, we propose that this
310 gene product should be called MTCL2 instead of SOGA. This conclusion is supported by
311 a recent study that identified SOGA as a CLASP2-binding protein by mass spectrometry
312 (Kruse et al., 2017). This conclusion is also supported by our observation that MTCL2
313 knockdown did not induce LC3-positive autophagosomes in HepG2 cells (Supplementary
314 Fig. 3). In addition, we have to mention that we failed to confirm the presence of the
315 putative internal signal sequence as well as Atg16- and Rab5-binding motifs in the
316 MTCL2 sequence, all of which were discussed in a previous paper (see Fig. 1A, boxed
317 illustration) (Cowherd et al., 2010).

318

Consistent with the overall homology with MTCL1, MTCL2 exhibits several similar

319 features of MTCL1. It shows homo-oligomerization activity via the coiled-coil region
320 (Supplementary Fig. 4), localizes to the Golgi membrane, and interacts with MTs through
321 the C-terminal region. We also demonstrated that, similar to MTCL1, MTCL2
322 knockdown in RPE1 cells impaired directional migration without significantly affecting
323 the Golgi repolarization (Sato et al., 2014). On the other hand, we noticed that MTCL2
324 has characteristic features distinct from those of MTCL1. The most striking difference is
325 that MTCL2 only has a single MT-binding region in the C-terminus, and this C-MTBD
326 lacks the MT-stabilizing activity observed for MTCL1 C-MTBD. This indicates that the
327 major role of MTCL2 is to crosslink and accumulate MTs on the Golgi membrane (Fig.
328 9A and B). MTCL1 was named after its MT crosslinking activity via N-MTBD (Sato et
329 al., 2013). However, accumulating data demonstrated that the MT-stabilization activity of
330 C-MTBD is essential for its physiological roles (Satake et al., 2017). In addition, in
331 cultured cells, we demonstrated that the MT stabilization activity of MTCL1 is
332 fundamentally required for the stable development of the Golgi-nucleated MTs, which
333 are subsequently crosslinked by N-MTBD (Fig. 9B) (Sato et al., 2014). Therefore,
334 together with the present results that MTCL1 and 2 associate with MTs in a mutually
335 exclusive manner without forming a heterocomplex, these results suggest that these two
336 members of the MTCL family exert distinct roles for MT organization on the Golgi
337 membrane. MTCL1 mainly supports the development of Golgi-nucleated MTs by
338 stabilizing their elongation, whereas MTCL2 crosslinks and accumulates these MTs
339 around the Golgi (Fig. 9B).

340 Interestingly, in RPE1 cells at the wound edge, MTCL2 knockdown led to the
341 separation of the centrosome and Golgi ribbon. In these cells, MTs emanating from the
342 centrosome and those associated with the Golgi were clearly distinct, although both of

343 them independently invaded lamellipodia. These results are consistent with a previous
344 work demonstrating that disconnecting the Golgi ribbon from the centrosome prevents
345 directional migration (Hurtado et al., 2011), and raise the intriguing possibility that the
346 MT crosslinking activity of MTCL2 plays an important role in integrating centrosomal
347 and Golgi-associated MTs. To establish directional cell migration, repolarization of the
348 Golgi to the wound (Etienne-Manneville and Hall, 2001; Kupfer et al., 1982) and
349 development of the Golgi ribbon structure (Miller et al., 2009; Rivero et al., 2009) have
350 been shown to be required. The present results proposed that the integration of
351 centrosomal and Golgi-associated MTs represents the third requirement for directional
352 migration. MTCL2 knockdown-dependent separation of the centrosome and the Golgi
353 ribbon was not clearly observed in HeLa-K cells, which did not show active migration.
354 Therefore, the integration of centrosomal and Golgi-derived MTs by MTCL2 might be
355 particularly important for actively migrating cells, in which MTs must be subjected to
356 various mechanical stresses (Etienne-Manneville, 2013).

357 In addition to the effects on MTs, MTCL2 knockdown caused expansion of the
358 crescent-like morphology of the Golgi ribbon along the nucleus. Since RNAi-resistant
359 MTCL2 mutant lacking the C-MTBD (MTCL2 Δ C-MTBD) did not rescue this phenotype,
360 crosslinking and accumulation of the Golgi-associated MTs by MTCL2 may indirectly
361 facilitate the clustering of the Golgi ribbon (Fig. 9A). However, at present, we cannot
362 conclusively propose this model as MTCL2 Δ C-MTBD failed to localize to the Golgi and
363 diffusely distributed in the cytosol. This means that loss of C-MTBD leads to the loss of
364 Golgi association activity, and raises the possibility that the lack of rescue activity of
365 MTCL2 Δ C-MTBD might be due to the lack of Golgi-binding activity, but not due to the
366 lack of the MT-binding activity. Our deletion mutant analysis (Fig. 4) clearly indicated

367 that the N-terminal region was sufficient for the Golgi association. Therefore, loss of the
368 Golgi association activity in MTCL2 Δ C-MTBD was unexpected. One possible
369 explanation is that the Golgi association activity of MTCL2 is masked in the full-length
370 molecule by, for example, an intramolecular interaction, and MT binding through the C-
371 MTBD releases the inhibition. Examination of this model as well as identification of the
372 target molecule of MTCL2 for its Golgi localization (X in Fig. 9B) are important
373 directions for our future study.

374

375

Materials and methods

376

377 **Molecular biology**

378 The cDNA clone encoding full-length mouse MTCL2 (GenBank accession number:
379 AK147227) was purchased from Danaform (Kanagawa, Japan). After confirming
380 sequence identity with NM_001164663, a DNA fragment corresponding to the MTCL2
381 open reading frame was subcloned into an expression vector, pCAGGS-V5. Subsequently,
382 several deletion mutants of MTCL2 were constructed in pCAGGS-V5, pEGFP-c2
383 (Takara Bio Inc., Japan), or pMal-c5x (New England Biolabs). To establish heterogeneous
384 stable transformants, mouse MTCL2 and its mutants with or without a 6 × V5-tag were
385 subcloned in pOSTet15.1 (kindly provided by Y. Miwa, University of Tsukuba, Japan),
386 an Epstein–Barr virus (EBV)-based extrachromosomal vectors carrying a replication
387 origin (oriP) and replication initiation factor (EBNA-1) sufficient for autonomous
388 replication in human cells (Tanaka et al., 1999). Human and mouse MTCL1 cDNA
389 (GenBank accession numbers: AB018345 and AK147691, respectively) used were
390 described previously (Sato et al., 2013).

391

392 **Antibodies**

393 Anti-KIAA0802 pAb (W19) (Santa Cruz Biotechnology) and anti-SOGA1 polyclonal
394 antibody (pAb) (HPA043992) (Sigma-Aldrich) were used to detect MTCL1 and MTCL2,
395 respectively. To detect other proteins, the following antibodies were used: anti- α -tubulin
396 monoclonal Ab (mAb) (DM1A), anti-acetylated tubulin mAb (6-11B-1), anti-MAP4
397 mAb (H-300), and anti-GFP mAb (B-2) (Santa Cruz Biotechnology); anti-V5 mAb
398 (R960-25) (Thermo Fisher); anti-GM130 mAb (35/GM130), anti-GS28 (1/GS28) (BD

399 Transduction Laboratories); anti-GAPDH mAb (6C5) (Hytect ltd.); anti- β -tubulin (KMX-
400 1) (Upstate/Millipore); anti-pericentrin pAb (ab4448) (Abcam); LC3 mAb (M152-3)
401 (MBL, Japan).

402

403 **Cell culture and plasmid transfection**

404

405 HeLa-Kyoto (HeLa-K), HEK293T, and HepG2 cells were cultured in Dulbecco's
406 modified Eagle's medium (low glucose) (Nissui, Japan) containing 10% fetal bovine
407 serum, 100 U/mL penicillin, 100 μ g/mL streptomycin, and 1 mM glutamine at 37°C in
408 5% CO₂. Immortalized human pigment epithelial cells, hTERT-RPE1 (RPE1) cells were
409 maintained in a 1:1 mixture of DMEM/Ham's F12 (FUJIFILM WAKO Pure Chemical
410 Corporation, Japan) containing 10% fetal bovine serum, 100 U/mL penicillin, 100 μ g/mL
411 streptomycin, 10 μ g/mL hygromycin B, and 1 mM glutamine at 37°C in 5% CO₂. When
412 subjected to immunofluorescent analysis, cells were seeded on coverslips settled down in
413 24-well plates and coated with atelocollagen (0.5 mg/mL IPC-50; KOKEN, Japan).
414 Plasmid transfections were performed using polyethyleneimine (Polysciences, Inc.) for
415 HEK293T cells or Lipofectamine LTX (Life Technologies Corporation) for HeLa-K cells
416 according to the manufacturer's instructions. To establish heterogenous stable HeLa-K
417 cells expressing mouse MTCL2 in a doxycycline-dependent manner, cells were
418 transfected with pOSTet15.1 expression vector encoding the appropriate MTCL2 cDNA.
419 The following day, cells were reseeded at one-twentieth of the cell density, and subjected
420 to selection using medium containing 800 μ g/mL G418 disulfate (Nacalai Tesque, Japan)
421 for more than 6 days. The surviving cells were used in the following experiments without
422 cloning.

423

424 **RNAi experiments and wound healing assays**

425

426 The siRNA oligonucleotide sequences used for MTCL2 knockdown in human cultured
427 cells were as follows: #2: 5'-GAGCGACCGAGAGAGCAUCC-3' and #5:
428 CUGAAGUACCGCUCGCUCUdTdT. As control, a non-silencing RNAi
429 oligonucleotide (All stars negative control siRNA: Qiagen) was used. Cells were seeded
430 on coverslips at densities of $1.2 \sim 4 \times 10^4$ cells, and transfected with siRNA
431 oligonucleotide at final concentrations of 10 – 17 nM using RNAiMax (Life Technologies
432 Corporation) according to the manufacturer's instructions. siRNA transfection was
433 repeated the day after medium change, and cells were subjected to immunofluorescence
434 analysis on day 3. For rescue experiments, heterogeneous stable HeLa-K cells expressing
435 mouse MTCL2 were subjected to a similar protocol, except that 100 ng/mL of
436 doxycycline was always included in the medium after the 1st siRNA transfection. For
437 wound healing analysis, HeLa-K cells subjected to RNAi were scratched with a
438 micropipette tip on day 4. RPE1 cells were seeded at 5×10^4 cells in one compartment of
439 35 mm glass bottom culture dish separated into 4 compartments (Greiner, 627870) after
440 coating with 10 μ g/mL fibronectin (FUJIFILM, Japan, 063-05591), and siRNA
441 transfections were performed as described above. Wounds were made on day 4 by
442 scratching cell monolayers with a micropipette tip and subjected to live imaging.

443

444 **Cell extraction and western blotting**

445

446 Cell extracts were prepared by adding RIPA buffer (25mM Tris/HCl pH 7.5, 150mM

447 NaCl, 1% NP40, 1% deoxycholic acid, 0.1% SDS) containing protease inhibitor cocktail
448 (Sigma, P8340) followed by brief sonication and centrifugation ($15,000 \times g$, 15 min). For
449 tissue distribution analysis of MTCL2, the mouse tissue lysates prepared in a previous
450 study were used (Satake et al., 2017). Samples were separated by SDS-PAGE and then
451 transferred to polyvinylidene difluoride membranes. Blots were incubated in blocking buffer
452 containing 5% (w/v) dried skim milk in PBST (8.1mM Na₂HPO₄·12H₂O, 1.47mM
453 KH₂PO₄, 137mM NaCl, 2.7mM KCl, and 0.05% Tween 20) followed by overnight
454 incubation with the appropriate antibodies diluted in blocking buffer. Dilutions of anti-
455 SOGA pAb and anti-GAPDH mAb were 1:1000 and 1:5000, respectively. Secondary
456 antibodies were diluted to 1:2,000. Blots were then exposed to horseradish peroxidase
457 (HRP)-conjugated secondary antibodies (GE Healthcare) diluted in blocking buffer for
458 60 min at RT and washed again. Blots were visualized using Immobilon Western
459 Chemiluminescent HRP Substrate (Millipore) or ECL western blotting detection system
460 (GE Healthcare), and chemiluminescence was quantified using the ImageQuant LAS4000
461 Luminescent Image Analyzer (GE Healthcare).

462

463 **Immunofluorescence staining**

464

465 Cells were fixed with cold methanol for 10 min at -20°C , followed by blocking with 10%
466 (v/v) fetal bovine serum in PBST. To visualize the Golgi localization of exogenous
467 MTCL2, cells were treated with modified PBST containing 0.5% TritonX-100 instead of
468 Tween20 for 10 min after fixation. Samples were then incubated with appropriate primary
469 antibodies diluted in TBST (10mM Tris-HCl, pH 7.5, 150mM NaCl, 0.01% (v/v) Tween
470 20) containing 0.1% (w/v) BSA for 45 min at RT, except for MTCL1 and 2 staining,

471 which were performed overnight at 4°C. After washing with PBST, samples were
472 visualized with the appropriate secondary antibodies conjugated with Alexa Fluor 488,
473 555, or 647 (Life Technologies Corporation) by incubating for 45min at RT. Antibodies
474 were diluted as follows: anti-KIAA0802 pAb (1/1000), anti-SOGA pAb (1/2000), anti- α -
475 tubulin mAb (1:1,000), anti-acetylated tubulin mAb (1:1,000), anti-V5 mAb (1:4,000),
476 anti-GM130 mAb (1:1,000), anti-GS28 mAb (1:300), anti-GFP mAb (1:2,000), anti-
477 MAP4 mAb (1:1000), anti- β -tubulin (1:2000), anti-pericentrin pAb (1:1000), and anti-
478 LC3 mAb (1:300). All secondary antibodies were used at a 1:2000 dilution. The nuclei
479 were counterstained with DAPI (4', 6-diamidino-2-phenylindole) (MBL, Japan) at a
480 1:2000 dilution in PBST during the final wash. For image acquisition, samples on
481 coverslips were mounted onto glass slides in Prolong Diamond Antifade Mountant
482 (Thermo Fisher).

483

484 **Image acquisition and processing**

485

486 High-resolution images were acquired using a Leica SP8 laser scanning confocal
487 microscopy system equipped with an HC PL APO 63x/1.40 Oil 2 objective, using the
488 Hybrid Detector in photon counting mode. To obtain super-resolution images,
489 HyVolution2 imaging was performed on the same system using Huygens Essential
490 software (Scientific Volume Imaging) (Borlinghaus and Kappel, 2016). To obtain wide
491 view images for quantification (for Figs. 5 and 6), conventional fluorescence images were
492 obtained using an AxioImager ZI microscope (Carl Zeiss, Oberkochen, Germany)
493 equipped with a Plan APCHROMAT 40 \times /0.95 objective using Orca II CCD camera
494 (Hamamatsu Photonics, Shizuoka, Japan). The laterally expanding angle of the Golgi

495 apparatus around nuclei and skewness of pixel intensity were quantified using the
496 “Measure” function of ImageJ software. For statistical analysis, photographs of several
497 fields containing ~40 cells with similar density were taken from two independent
498 experiments, and all cells in each field were subjected to quantification analysis to avoid
499 selection bias. In rescue experiments, ~100 cells expressing exogenous MTCL2 at similar
500 expression levels as endogenous one were collected from ~10 fields with similar cell
501 densities. For live cell imaging, differential interference contrast (DIC) images were
502 acquired using a Leica SP8 confocal microscopy system equipped with an HCX PL APO
503 10x/0.40 objective using a 488nm laser line. Areas newly covered by migrated cells
504 during wound healing for 440min were estimated using the “Measure” function of ImageJ
505 software and normalized by the length of the corresponding wound edge at time 0.

506

507 **MT-binding assay**

508

509 MBP (maltose binding protein) or MBP-mMTCL1 CT1 were purified from the soluble
510 fraction of *E. coli* according to the standard protocol, and dialyzed against BRB buffer
511 (80 mM PIPES-KOH pH 6.8, 1 mM MgCl₂, 1 mM EGTA). Each MBP protein was
512 incubated with taxol-stabilized MTs (both final concentrations of the sample protein and
513 α/β -tubulin heterodimer were 0.5 mg/mL) in BRB supplemented with 1.5 mM MgCl₂
514 and 1mM GTP for 15 min at RT, and subjected to centrifugation (200,000 × g) for 20 min
515 at 25°C on a cushion of 40% glycerol in BRB buffer. After carefully removing the
516 supernatant and glycerol cushion, the resultant MT pellet was gently washed with PBST
517 3 times and solubilized with SDS sample buffer (10% β -mercaptoethanol, 125 mM Tris-
518 HCl, pH 6.8, 2% SDS, 10% glycerol, and 0.005% bromophenol blue) for subsequent

519 SDS-PAGE analysis.

520

521 **Immunoprecipitation and pull-down experiments**

522

523 HeLa-K cells ($\sim 5 \times 10^6$ cells) were solubilized in 1mL lysis buffer (20mM Tris-HCl, pH
524 7.5, 150mM NaCl, 1% NP-40, 1mM DTT) containing a cocktail of protease and
525 phosphatase inhibitors (Roche Applied Science) for 30 min at 4°C, briefly sonicated, and
526 centrifuged at $15,000 \times g$ for 30 min. The resulting supernatants were mixed with
527 Dynabeads Protein G (Thermo Fisher) conjugated with 2 μ g of anti-MTCL1 antibody for
528 ~ 2 h at 4°C. Immunoprecipitates were boiled in SDS sample buffer and subjected to
529 western blot analysis. In pull-down experiments, HEK293T cells were transfected with
530 appropriate expression vectors and subjected to the same procedure as described above,
531 except that streptavidin-conjugated Sepharose (GE Healthcare) was used instead of
532 Dynabeads.

533

534

535

Acknowledgement

536

537 The authors thank Yoshihiro Miwa (University of Tsukuba) for providing the pOSTet15.1
538 expression vector gift. We would like to thank Editage (www.editage.com) for English
539 language editing. This work was supported by KAKENHI (to A.S.) (Grant Numbers
540 16H04765 and 19H03228) of the Ministry of Education, Culture, Sports, Science and
541 Technology (MEXT) of Japan.

542

543

Author contributions

544

545 A.S. planned and performed the experiments, interpreted the results, and wrote the paper.
546 R.M., M.M, S.M, and Y.I. performed the experiments.

547

548

Conflict of interest

549

550 The authors declare no competing financial interests.

551

552

Figure legends

553

554 **Figure 1. MTCL2 is expressed predominantly as an 180kDa full-length protein**

555 **without cleavage.** (A) Predicted molecular structure of mouse MTCL2 (mMTCL2) and

556 its amino acid sequence homology with mouse MTCL1 (mMTCL1). CC (dark blue)

557 indicates the region with highest score (> 0.85) of coiled-coil prediction, whereas CCL

558 (light blue) indicates the region with moderate score (>0.4) ([https://embnet.vital-](https://embnet.vital-it.ch/software/COILS_form.html)

559 [it.ch/software/COILS_form.html](https://embnet.vital-it.ch/software/COILS_form.html)). A black bar labeled 'epitope' indicates the position of

560 the antigen peptide against which the used antibody was generated (commercially

561 available anti-SOGA antibody). The boxed illustrations in the bottom indicate the position

562 of mouse SOGA (mSOGA) in comparison with mMTCL2, and summarize the arguments

563 in the paper reporting SOGA (Cowherd et al., 2010). Green bar indicates the predicated

564 position of the internal signal sequence, whereas green dotted arrows indicate the

565 predicted positions of cleavages. We failed to confirm all arguments indicated here by

566 ourselves. (B, C) Sequence alignment of the N and C-terminal region of mouse MTCL1

567 and 2. The MTCL1 sequence surrounded by bold line corresponds to the N- and C-MTBD

568 (B and C, respectively). Red line in C indicates the region where MTCL2 sequence

569 significantly diverges from that of MTCL1 C-MTBD. (D) Western blotting analysis to

570 estimate the molecular mass of MTCL2 expressed in various cultured cells. In lane 1~3,

571 cell extracts of HEK293T expressing exogenously expressed V5-mMTCL2 were loaded

572 after indicated dilution. In other lanes, extracts of indicated culture cells with or without

573 MTCL2 knockdown were loaded. NS: non-silencing control. #2 and #5 indicate different

574 siRNA oligonucleotides for MTCL2. (E) Tissue distribution of MTCL2. Total extracts

575 from the indicated mouse tissues (25 μ g/lane) were loaded for western blotting analysis

576 using anti-SOGA antibody. In lane 1, total cell extracts of HEK293T expressing

577 exogenously expressed V5-mMTCL2 were loaded as a positive control.

578

579 **Figure 2. MTCL2 specifically colocalizes with stable perinuclear microtubules.** (A-

580 C) HeLa-K cells were stained with anti-SOGA (MTCL2) together with anti- α -tubulin (A),

581 anti-acetylated tubulin (anti-Ac-tub) (B) or anti-GM130 antibody (C). Note that the

582 granular signal of MTCL2 specifically concentrates on the perinuclear MTs but not on

583 the peripheral MTs, and partially co-localizes with GM130. Scale bars, 10 μ m. (D) HeLa-

584 K cells were triply stained with anti-SOGA, anti-GM130, and anti-acetylated tubulin as

585 indicated. Shown are super-resolution microscopic images. Scale bars, 5 μ m and 2 μ m

586 (enlarged panels).

587

588 **Figure 3. Preferential localization to the Golgi-associated MTs is the specific feature**

589 **of MTCL protein family members.** HeLa-K cells were subjected to immunofluorescent

590 analysis using anti-MTCL1, MTCL2 (SOGA), or MAP4 antibodies together with anti- α -

591 tubulin and anti-GS28 (Golgi protein) antibody. At the bottom, similar staining data using

592 anti-acetylated tubulin antibody are shown for comparison. Bars, 20 μ m and 5 μ m (insets).

593

594 **Figure 4. MTCL2 associates with MTs and the Golgi membrane independently.** (A)

595 MTCL2 deletion mutants used in this study. (B) Subcellular localization of V5-tagged

596 deletion mutants of mouse MTCL2 in HeLa-K cells. Cells were triply stained with anti-

597 V5, anti- β -tubulin, and anti-GM130 antibodies. In the bottom panel, data of cells

598 expressing V5-mMTCL1 N-terminal fragment (1-916) were shown for comparison. Scale

599 bar, 20 μ m. (C) The C-terminal fragment of mMTCL2 directly binds to MTs. MBP-fused

600 mMTCL2 CT1 purified from *E.coli*. was examined for MT pull-down experiments. MBP-

601 mMTCL2 CT1 but not MBP was found to be specifically precipitated only when taxol-
602 stabilized MTs were included.

603

604 **Figure 5. MTCL2 depletion reduces the perinuclear accumulation of MTs in a C-**

605 **MTBD dependent manner.** (A) HeLa-K cells stably harboring pOSTet15.1 expression

606 vector for mouse MTCL2 were transfected with siRNA oligonucleotides for control or

607 MTCL2 knockdown (#2) in the presence or absence of 100nM doxycycline, and doubly

608 stained with anti-SOGA (MTCL2) and anti- α -tubulin antibody, as indicated on the left.

609 Note that cells subjected to control RNAi show MT accumulations at the perinuclear

610 region where MTCL2 concentrated in the absence of doxycycline (without exogenous

611 expression of mouse MTCL2). Such accumulation of MTs disappeared in MTCL2

612 knockdown cells (-dox), whereas exogenous expression of RNAi-resistant MTCL2

613 (+dox) strongly restore the accumulation. Bar: 20 μ m. (B) Extent of MT accumulation

614 was quantitatively estimated by calculating the skewness of the pixel intensity

615 distribution for tubulin fluorescence signal in each cell. Top panel shows typical data on

616 the distribution, indicating that the asymmetries of tubulin signal distribution are

617 compromised in MTCL2 knockdown cells. Bottom is box plot combined with beeswarm

618 plot of the skewness distribution in each condition. The lines within each box represent

619 medians. Data represent the results of the indicated number (n) of cells from two

620 independent experiments. ** p<0.01, estimated by the Wilcoxon test. NS: no significant

621 difference. (C) HeLa-K cells stably harboring pOSTet15.1 expression vector for mouse

622 MTCL2 Δ C-MTBD were subjected to the same experimental procedure as in (A). Note

623 that MT accumulation was not restored by expression of mouse MTCL2 Δ C-MTBD. Bar:

624 20 μ m. (D) MT accumulation data in (C) was quantitatively analyzed as in (B). Data

625 represent the results of the indicated number (n) of cells from two independent
626 experiments. ** $p < 0.01$, estimated by the Wilcoxon test.

627

628 **Figure 6. MTCL2 depletion significantly expands the Golgi ribbon structures. (A)**

629 HeLa-K cells stably harboring pOSTet15.1 expression vector for mouse MTCL2 were
630 transected with siRNA oligonucleotide for control or MTCL2 knockdown (#2) in the
631 presence or absence of 100nM doxycycline, and doubly stained with anti-SOGA
632 (MTCL2) and anti-GM130 antibodies, as indicated on the left. Note that cells subjected
633 to control RNAi show compact Golgi ribbon structures at one side of the perinuclear
634 region. Such Golgi ribbon structures become laterally expanded around the nucleus in
635 MTCL2 knockdown cells (-dox), whereas exogenous expression of RNAi-resistant
636 MTCL2 (+dox) strongly restore their compactness. Bar: 20 μm . (B) Quantification of

637 Golgi ribbon expanding angle (θ) around the nuclei (top panel) in each condition. Data
638 represent the results of the indicated number (n) of cells from two independent
639 experiments. ** $p < 0.01$, estimated by the Wilcoxon test. NS: no significant difference.

640 (C) HeLa-K cells stably harboring pOSTet15.1 expression vector for mouse MTCL2 $\Delta\text{C-}$
641 MTBD were subjected to the same experimental procedure as in (A). Note that
642 compactness of Golgi ribbon was not restored by expression of mouse MTCL2 $\Delta\text{C-}$
643 MTBD. Bar: 20 μm . (D) Quantitative analysis as in (B). Data represent the results of the
644 indicated number (n) of cells from two independent experiments. ** $p < 0.01$, estimated
645 by the Wilcoxon test.

646

647 **Figure 7. MTCL2 depletion results in defective cell migration. (A)** Confluent

648 monolayers of HeLa-K cells subjected to control or MTCL2 RNAi were fixed and stained

649 with the indicated antibodies 6h after wounding. Cells facing the wound edges (white
650 dotted lines) are shown. Bars, 50 μm . Note that MTCL2-depleted cells did not polarize
651 MT arrays toward the wound. Right panel indicates the percentage of wound-edge cells
652 with correctly oriented Golgi, defined as those falling in the indicated quadrant (white
653 line) in relation to the wound edge. Data represent the means \pm S.D. for the indicated
654 number (n) of cells from two independent experiments. NS: no significant difference
655 estimated by the Student's t-test assuming the two-tailed distribution and two-sample
656 unequal variance. (B) Differential interference contrast (DIC) images of wound healing
657 RPE1 cells at 0 min and 7h 20 min after wounding. White dotted line delineated the
658 wound edges. Bars: 200 μm . Right panel indicates quantified data on the areas newly
659 buried by cells after wounding. Data represent the mean \pm S.D. of 44 fields taken from
660 two independent experiments. $**p < 0.01$, estimated by the Student's t-test assuming the
661 two-tailed distribution and two-sample unequal variance. (C) RPE1 cells subjected
662 wound healing analysis in (B) were fixed and stained with the indicated antibodies. Cells
663 facing the wound edges are shown. Right panels are enlarged view. Note that MTCL2-
664 depleted cells exhibit the separation of the centrosome (white arrowheads) and Golgi,
665 from which MTs are emanating rather independently. Sometimes the centrosome shows
666 significant detachment from the perinuclear region (yellow arrowhead). Bars, 50 μm and
667 20 μm (enlarged right panels). (D) Golgi orientation was quantified for wound healing
668 RPE1 cells as indicated in (A). Data represent the means \pm S.D. for the indicated number
669 (n) of cells from two independent experiments. NS: no significant difference estimated
670 by the Student's t-test assuming the two-tailed distribution and two-sample unequal
671 variance. (E) Percentage of wound-edge cells with Golgi detached from the centrosome.
672 Data represent the means \pm S.D. for the indicated number (n) of cells from two

673 independent experiments. $**p < 0.01$, estimated by the Student's t-test assuming the two-
674 tailed distribution and two-sample unequal variance.

675

676 **Figure 8. MTCL1 and 2 differentially regulate Golgi-associated MTs.** (A) MTCL1
677 and 2 localize on MTs in a mutually exclusive manner. HeLa-K cells stably harboring
678 expression vector for V5-tagged mouse MTCL2 were cultured in the presence of
679 100ng/mL doxycycline, and stained with the indicated antibodies. Shown are super-
680 resolution microscopic images. Scale bars, 5 μ m and 1 μ m (enlarged panels). (B) HeLa-K
681 cells transfected with control or MTCL1 siRNA oligonucleotide were subjected to
682 immunoprecipitation with anti-MTCL1 antibody. (C) HeLa-K cells transfected with
683 control or MTCL2 siRNA oligonucleotide were fixed and stained with the indicated
684 antibodies. Bar, 10 μ m. (D) HeLa-K cells exogenously expressing GFP, GFP-human
685 MTCL1 C-MTBD, or GFP-mouse MTCL2 C-MTBD were immunostained with the
686 indicated antibodies. Bar, 20 μ m. (E) Total cells extracts of HEK293 cells exogenously
687 expressing GFP, GFP-human MTCL1 C-MTBD, or GFP-mouse MTCL2 C-MTBD were
688 subjected to western blotting analysis using the indicated antibodies.

689

690 **Figure 9. Model for the mechanisms by which MTCL2 regulates Golgi-associated**
691 **MTs, Golgi ribbon morphology, and cell polarity.** (A) MTCL2 parallel dimers
692 crosslink and accumulate MTs on the Golgi membrane, and thereby facilitate the
693 clustering of Golgi stacks into a compact Golgi ribbon. (B) MTCL1 mainly supports the
694 development of the Golgi-nucleated MTs by stabilizing their elongation, whereas MTCL2
695 crosslinks and accumulates MTs around the Golgi and facilitate lateral clustering of Golgi
696 stacks. The present results further indicate a possibility that MTCL2 crosslinks the Golgi-

697 associated MTs with the centrosomal MTs, and thereby integrate these two subsets of MT
698 populations (not illustrated here). X indicates putative target of MTCL2 mediating its
699 Golgi association.

700

References

701

702 **Abdul Kader, M., Satake, T., Yoshida, M., Hayashi, I. and Suzuki, A.** (2017). Molecular basis of the
703 microtubule-regulating activity of microtubule crosslinking factor 1. *PLoS One* **12**, e0182641.

704 **Akhmanova, A. and Hoogenraad, C. C.** (2015). Microtubule minus-end-targeting proteins. *Curr. Biol.*
705 **25**, R162–R171.

706 **Baas, P. W., Rao, A. N., Matamoros, A. J. and Leo, L.** (2016). Stability properties of neuronal
707 microtubules. *Cytoskeleton* **73**, 442–460.

708 **Bacallao, R., Antony, C., Dotti, C., Karsenti, E., Stelzer, E. H. K. and Simons, K.** (1989). The
709 subcellular organization of Madin-Darby canine kidney cells during the formation of a polarized
710 epithelium. *J. Cell Biol.* **109**, 2817–2832.

711 **Bartolini, F. and Gundersen, G. G.** (2006). Generation of noncentrosomal microtubule arrays. *J. Cell*
712 *Sci.* **119**, 4155–63.

713 **Bergmann, J. E., Kupfer, A. and Singer, S. J.** (1983). Membrane insertion at the leading edge of motile
714 fibroblasts. *Proc. Natl. Acad. Sci. U. S. A.* **80**, 1367–1371.

715 **Borlinghaus, R. T. and Kappel, C.** (2016). HyVolution—the smart path to confocal super-resolution.
716 *Nat. Methods* **13**, i–iii.

717 **Chabin-Brion, K., Marceiller, J., Perez, F., Settegrana, C., Drechou, A., Durand, G. and Poüs, C.**
718 (2001). The Golgi complex is a microtubule-organizing organelle. *Mol. Biol. Cell* **12**, 2047–60.

719 **Chapin, S. J. and Bulinski, J. C.** (1991). Non-neuronal 210 x 10(3) Mr microtubule-associated protein
720 (MAP4) contains a domain homologous to the microtubule-binding domains of neuronal MAP2 and
721 tau. *J. Cell Sci.* **98 (Pt 1)**, 27–36.

722 **Combs, T. P. and Marliss, E. B.** (2014). Adiponectin signaling in the liver. *Rev. Endocr. Metab. Disord.*
723 **15**, 137–147.

- 724 **Conduit, P. T., Wainman, A. and Raff, J. W.** (2015). Centrosome function and assembly in animal
725 cells. *Nat. Rev. Mol. Cell Biol.* **16**, 611–624.
- 726 **Cowherd, R. B., Asmar, M. M., Alderman, J. M., Alderman, E. a, Garland, A. L., Busby, W. H.,**
727 **Bodnar, W. M., Rusyn, I., Medoff, B. D., Tisch, R., et al.** (2010). Adiponectin lowers glucose
728 production by increasing SOGA. *Am. J. Pathol.* **177**, 1936–1945.
- 729 **Efimov, A., Kharitonov, A., Efimova, N., Loncarek, J., Miller, P. M., Andreyeva, N., Gleeson, P.,**
730 **Galjart, N., Maia, A. R. R., McLeod, I. X., et al.** (2007). Asymmetric CLASP-Dependent
731 Nucleation of Noncentrosomal Microtubules at the trans-Golgi Network. *Dev. Cell* **12**, 917–930.
- 732 **Etienne-Manneville, S.** (2013). Microtubules in cell migration. *Annu. Rev. Cell Dev. Biol.* **29**, 471–499.
- 733 **Etienne-Manneville, S. and Hall, A.** (2001). Integrin-mediated activation of Cdc42 controls cell polarity
734 in migrating astrocytes through PKC ζ . *Cell* **106**, 489–498.
- 735 **Hahn, I., Voelzmann, A., Liew, Y. T., Costa-Gomes, B. and Prokop, A.** (2019). The model of local
736 axon homeostasis - Explaining the role and regulation of microtubule bundles in axon maintenance
737 and pathology. *Neural Dev.* **14**, 1–28.
- 738 **Hurtado, L., Caballero, C., Gavilan, M. P., Cardenas, J., Bornens, M. and Rios, R. M.** (2011).
739 Disconnecting the Golgi ribbon from the centrosome prevents directional cell migration and
740 ciliogenesis. *J. Cell Biol.* **193**, 917–33.
- 741 **Kruse, R., Krantz, J., Barker, N., Coletta, R. L., Rafikov, R., Luo, M., Højlund, K., Mandarino, L.**
742 **J. and Langlais, P. R.** (2017). Characterization of the CLASP2 protein interaction network
743 identifies SOGA1 as a microtubule-associated protein. *Mol. Cell. Proteomics* **16**, 1718–1735.
- 744 **Kupfer, A., Louvard, D. and Singer, S. J.** (1982). Polarization of the Golgi apparatus and the
745 microtubule-organizing center in cultured fibroblasts at the edge of an experimental wound. *Proc.*
746 *Natl. Acad. Sci. U. S. A.* **79**, 2603–2607.
- 747 **Meiring, J. C. M., Shneyer, B. I. and Akhmanova, A.** (2020). Generation and regulation of microtubule

- 748 network asymmetry to drive cell polarity. *Curr. Opin. Cell Biol.* **62**, 86–95.
- 749 **Miller, P. M., Folkmann, A. W., Maia, A. R. R., Efimova, N., Efimov, A. and Kaverina, I.** (2009).
750 Golgi-derived CLASP-dependent microtubules control Golgi organization and polarized trafficking
751 in motile cells. *Nat. Cell Biol.* **11**, 1069–80.
- 752 **Mogensen, M. M., Tucker, J. B. and Stebbings, H.** (1989). Microtubule polarities indicate that
753 nucleation and capture of microtubules occurs at cell surfaces in *Drosophila*. *J. Cell Biol.* **108**,
754 1445–1452.
- 755 **Muroyama, A. and Lechler, T.** (2017). Microtubule organization, dynamics and functions in
756 differentiated cells. *Dev.* **144**, 3012–3021.
- 757 **Nishita, M., Satake, T., Minami, Y. and Suzuki, A.** (2017). Regulatory mechanisms and cellular
758 functions of non-centrosomal microtubules. *J. Biochem.* **109**, 20029–20034.
- 759 **Oddoux, S., Zaal, K. J., Tate, V., Kenea, A., Nandkeolyar, S. A., Reid, E., Liu, W. and Ralston, E.**
760 (2013). Microtubules that form the stationary lattice of muscle fibers are dynamic and nucleated at
761 golgi elements. *J. Cell Biol.* **203**, 205–213.
- 762 **Pepperkok, R., Bre, M. H., Davoust, J. and Kreis, T. E.** (1990). Microtubules are stabilized in
763 confluent epithelial cells but not in fibroblasts. *J. Cell Biol.* **111**, 3003–3012.
- 764 **Rivero, S., Cardenas, J., Bornens, M. and Rios, R. M.** (2009). Microtubule nucleation at the cis-side of
765 the Golgi apparatus requires AKAP450 and GM130. *EMBO J.* **28**, 1016–1028.
- 766 **Satake, T., Yamashita, K., Hayashi, K., Miyatake, S., Tamura-Nakano, M., Doi, H., Furuta, Y.,**
767 **Shioi, G., Miura, E., Takeo, Y. H., et al.** (2017). MTCL1 plays an essential role in maintaining
768 Purkinje neuron axon initial segment. *EMBO J.* **36**, 1227–1242.
- 769 **Sato, Y., Akitsu, M., Amano, Y., Yamashita, K., Ide, M., Shimada, K., Yamashita, A., Hirano, H.,**
770 **Arakawa, N., Maki, T., et al.** (2013). The novel PAR-1-binding protein MTCL1 has crucial roles
771 in organizing microtubules in polarizing epithelial cells. *J. Cell Sci.* **126**, 4671–4683.

- 772 **Sato, Y., Hayashi, K., Amano, Y., Takahashi, M., Yonemura, S., Hayashi, I., Hirose, H., Ohno, S.**
773 **and Suzuki, A.** (2014). MTCL1 crosslinks and stabilizes non-centrosomal microtubules on the
774 Golgi membrane. *Nat. Commun.* **5**, 5266.
- 775 **Tanaka, J., Miwa, Y., Miyoshi, K., Ueno, A. and Inoue, H.** (1999). Construction of Epstein-Barr virus-
776 based expression vector containing mini-oriP. *Biochem. Biophys. Res. Commun.* **264**, 938–43.
- 777 **Vorobjev, I. A. and Nadezhdina, E. S.** (1987). The Centrosome and Its Role in the Organization of
778 Microtubules. *Int. Rev. Cytol.* **106**, 227–293.
- 779 **Wei, J. H. and Seemann, J.** (2010). Unraveling the Golgi ribbon. *Traffic* **11**, 1391–1400.
- 780 **Wu, J. and Akhmanova, A.** (2017). Microtubule-Organizing Centers. *Annu. Rev. Cell Dev. Biol.* **33**,
781 annurev-cellbio-100616-060615.
- 782 **Wu, J., de Heus, C., Liu, Q., Bouchet, B. P., Noordstra, I., Jiang, K., Hua, S., Martin, M., Yang, C.,**
783 **Grigoriev, I., et al.** (2016). Molecular Pathway of Microtubule Organization at the Golgi
784 Apparatus. *Dev. Cell* **39**, 44–60.
- 785 **Yadav, S., Puri, S. and Linstedt, A. D.** (2009). A primary role for golgi positioning in directed
786 secretion, cell polarity, and wound healing. *Mol. Biol. Cell* **20**, 1728–1736.
- 787 **Yang, C., Wu, J., de Heus, C., Grigoriev, I., Liv, N., Yao, Y., Smal, I., Meijering, E., Klumperman,**
788 **J., Qi, R. Z., et al.** (2017). EB1 and EB3 regulate microtubule minus end organization and Golgi
789 morphology. *J. Cell Biol.* **216**, 3179–3198.
- 790

Figure 1




Figure 2




Figure 3




Figure 4






Figure 5


A



B



C



D






Figure 6


A



B



C



D




Figure 7






Figure 8


A




B



C



D



E





Figure 9

A



B

